Published in Drug Week, August 24th, 2007
At June 30, 2007, NUCRYST had $20.2 million in cash and short term investments. Further financial information follows at the end of the release.
"NUCRYST continued to advance our product development strategy in the first half of 2007," said Scott H. Gillis, President & CEO, NUCRYST Pharmaceuticals. "We continued with our preclinical work for gastroenterology...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.